Oruka Therapeutics, Inc. ORKA 深 沪
等待开盘 02-10 09:30:00 美东时间
33.26
+0.210
+0.64%
华盛通- 最 高33.89
- 今 开33.89
- 成交量 18.20万股
- 最 低 32.47
- 昨 收 33.05
- 总市值 16.10亿
- 52周最高 36.51
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 5.485
- 委 比 93.27%
- 总股本 4840.92万
- 历史最高 5922.804
- 量 比 0.45
- 振 幅 4.30%
- 历史最低 -0.636
- 每 手 1
- 风险率 8.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $50
UBS analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ:ORKA) with a Buy rating and announces Price Target of $50.
01-08 04:27
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Piper Sandler Initiates Coverage On Oruka Therapeutics with Overweight Rating, Announces Price Target of $75
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Oruka Therapeutics (NASDAQ:ORKA) with a Overweight rating and announces Price Target of $75.
2025-12-18 20:32
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $63
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $56 to $63.
2025-11-13 18:08
Oruka Therapeutics Q3 EPS $(0.55) Beats $(0.59) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.14 percent. This is a 62.33 percent increase over losses of $(1.46) per share from
2025-11-13 05:45
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics announced its participation in three upcoming investor conferences on November 10, 11, and 18, 2025, to discuss its novel biologics for treating chronic skin diseases like plaque psoriasis. A webcast and replay will be available on their investor website. Oruka’s mission is to develop therapies offering high clearance rates with infrequent dosing, potentially once or twice a year.
2025-10-29 11:00
